(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 5.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Innoviva's revenue in 2026 is $439,998,000.On average, 7 Wall Street analysts forecast INVA's revenue for 2026 to be $33,248,094,652, with the lowest INVA revenue forecast at $29,845,332,308, and the highest INVA revenue forecast at $37,306,845,999. On average, 7 Wall Street analysts forecast INVA's revenue for 2027 to be $35,903,838,680, with the lowest INVA revenue forecast at $28,360,687,592, and the highest INVA revenue forecast at $43,845,784,847.
In 2028, INVA is forecast to generate $36,757,057,858 in revenue, with the lowest revenue forecast at $28,771,041,946 and the highest revenue forecast at $45,666,371,069.